Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum PS128
- Development stage
- Phase 1
- Lead developer
- Bened Biomedical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum PS128 (reclassified as Lactiplantibacillus plantarum PS128) is a specific strain of probiotic bacteria identified for its psychobiotic properties. Developed by Bened Biomedical, PS128 is designed to modulate the gut-brain axis, thereby influencing neurological and psychological health. It has been shown in preclinical and clinical studies to regulate the levels of key neurotransmitters, including dopamine and serotonin, and to reduce inflammatory markers and stress hormones like cortisol. The strain is primarily investigated for its therapeutic potential in neurodevelopmental and neurodegenerative disorders such as Autism Spectrum Disorder (ASD) and Parkinson's disease, as well as psychiatric conditions like depression and anxiety. It is currently marketed as a medical food or dietary supplement in various regions while undergoing clinical evaluation for specific medical indications.
- Brand names
- NeuralliSolace
- Other names
- Lactiplantibacillus plantarum PS128L. plantarum PS128
Beyond the preview
Go deeper on lactobacillus plantarum PS128.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum PS128.